Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.48 |
| ▸ | METAP1 | P53582 | 2/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.47 |
| ▸ | CASR | P41180 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9239748 | 0.90 | ITGB3 (0.50) | METAP2METAP1SSTR4CASRLMNA | |
| SCHEMBL8334816 | 0.88 | CASR (0.48) | METAP2METAP1SSTR4CASRLMNA | |
| SCHEMBL7671144 | 0.88 | CASR (0.48) | METAP2METAP1SSTR4CASRLMNA | |
| SCHEMBL14304105 | 0.78 | CCR1 (0.61) | — | |
| SCHEMBL15665657 | 0.78 | SSTR4 (0.56) | METAP2METAP1SSTR4CASRLMNA | |
| SCHEMBL15665221 | 0.78 | SSTR4 (0.56) | METAP2METAP1SSTR4CASRLMNA | |
| SCHEMBL15665222 | 0.78 | SSTR4 (0.56) | METAP2METAP1SSTR4CASRLMNA | |
| SCHEMBL15665069 | 0.78 | SSTR4 (0.56) | METAP2METAP1SSTR4CASRLMNA | |
| SCHEMBL15665589 | 0.78 | SSTR4 (0.56) | METAP2METAP1SSTR4CASRLMNA | |
| SCHEMBL15665071 | 0.78 | SSTR4 (0.56) | METAP2METAP1SSTR4CASRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020049199-A1 | N-linked carbamates and ureas of heterocyclic thioesters | GLIAMED, INC. | 2002-04-25 | — | — | US | claimed |
| US-20020049199-A1 | N-linked carbamates and ureas of heterocyclic thioesters | GLIAMED, INC. | 2002-04-25 | — | — | US | disclosed |
| US-6274607-B1 | INHIBITORS OF PEPTIDYL-PROLYL ISOMERASE, OR ROTAMASE ENZYME ACTIVITY; DO NOT EXERT ANY IMMUNOSUPPRESSIVE ACTIVITY IN ADDITION TO THEIR NEUROTROPHIC ACTIVITY; BIOAVAILABILITY; POTENCY | GPI NIL HOLDINGS, INC. | 2001-08-14 | — | — | US | disclosed |
| US-5958949-A | INHIBITORS OF THE ENZYME ACTIVITY ASSOCIATED WITH IMMUNOPHILIN PROTEINS, PARTICULARLY PEPTIDYL-PROLYL ISOMERASE, OR ROTAMASE, ENZYME ACTIVITY; TREATMENT OF NERVOUS SYSTEM DISORDERS | GPI NIL HOLDINGS INC. (US) | 1999-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049199-A1 | N-linked carbamates and ureas of heterocyclic thioesters | FKBP8, FKBP1A, FKBP3 | METAP2 360/4885METAP1 277/4885SSTR4 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.